InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

Current share price for MSB : $1.695 0.01 (0.59%)+

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$2,206 Files FDA Submission 21 Nov 2006 9:41AM $1.660 $1.695 risen by 2.11%
$2,206 Stem Cell Heart Attack Trial-Positive Preclinical Results 14 Nov 2006 9:37AM $1.655 $1.695 risen by 2.42%
$2,206 Commitments Test Entity - First Quarter Report 30 Oct 2006 10:48AM $1.435 $1.695 risen by 18.12%
$2,206 Major stem cell patent granted in US 18 Oct 2006 9:03AM $1.480 $1.695 risen by 14.53%
$2,206 Investment in Angioblast for Phase II Cardiovascular Trial 21 Sep 2006 11:42AM $1.180 $1.695 risen by 43.64%
$2,206 Heart Function Improves in Stem Cell Trials 19 Sep 2006 10:03AM $1.235 $1.695 risen by 37.25%
$2,206 Preliminary Final Report/Full Year Accounts 13 Sep 2006 6:02PM $1.180 $1.695 risen by 43.64%
$2,206 Stem Cell Bone Repair Trials Produce Outstanding Results 22 Aug 2006 1:32PM $1.340 $1.695 risen by 26.49%
$2,206 Commitments Test Entity - Fourth Quarter Report 27 Jul 2006 10:59AM $1.330 $1.695 risen by 27.44%
$2,206 Locks in next stage of Growth 20 Jul 2006 9:54AM $1.320 $1.695 risen by 28.41%
$2,206 Trading Halt 18 Jul 2006 10:56AM n/a $1.695 n/a
$2,206 Targets major cartilage markets 4 Jul 2006 10:22AM $1.410 $1.695 risen by 20.21%
$2,206 Achieves major milestones/Positive results/Commercialisation 7 Jun 2006 11:04AM $1.630 $1.695 risen by 3.99%
$2,206 Positive results in preclinical trials for heart failure 22 May 2006 10:41AM $1.400 $1.695 risen by 21.07%
$2,206 Significant Progress in Clinical Trials 16 May 2006 9:32AM $1.380 $1.695 risen by 22.83%
$2,206 Commitments Test Entity - Third Quarter Report 28 Apr 2006 4:16PM $1.490 $1.695 risen by 13.76%
$2,206 Positive results confirm spinal fusion as major market 27 Apr 2006 9:42AM $1.600 $1.695 risen by 5.94%
$2,206 First Adult Stem Cells for Long Bone Fracture Patient 3 Apr 2006 11:45AM $1.800 $1.695 fallen by 5.83%
$2,206 Next generation drug eluting stent technology 22 Mar 2006 9:48AM $1.690 $1.695 risen by 0.30%
$2,206 Half Yearly Report & Half Year Accounts 13 Mar 2006 12:19PM $1.850 $1.695 fallen by 8.38%
$2,206 Pre-Clinical Studies validate universal donor business model 13 Feb 2006 9:16AM $1.645 $1.695 risen by 3.04%
$2,206 Commitments Test Entity - Second Quarter Report 31 Jan 2006 5:02PM $1.290 $1.695 risen by 31.40%
$2,206 Key Australian Adult Stem Cell Patent Granted 17 Jan 2006 11:04AM $1.200 $1.695 risen by 41.25%
$2,206 Australian Government awards $2.7m 21 Dec 2005 9:21AM $1.160 $1.695 risen by 46.12%
$2,206 Adult Stem Cell Heart Trial Update 19 Dec 2005 9:59AM $1.130 $1.695 risen by 50%

1176 - 1200 of 1214 results

Page 48 of 49

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.